---
title: "ImmuneOnco Biopharmaceuticals (Shanghai) (1541) stock"
url: "https://aibio.space/companies/immuneonco-biopharmaceuticals-shanghai/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKEX: 1541), China. The directory classifies it as Pharmaceuticals: Major."
---

1541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKEX · China

# ImmuneOnco Biopharmaceuticals (Shanghai) (1541) news

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a public biotech or pharmaceutical company listed on HKEX under the ticker 1541, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

## Latest ImmuneOnco Biopharmaceuticals (Shanghai) news

We have not published a story on ImmuneOnco Biopharmaceuticals (Shanghai) yet. When there is news, it will appear here.

## ImmuneOnco Biopharmaceuticals (Shanghai) at a glance

- **Ticker**: 1541

- **Listing**: HKEX

- **Country**: China

### Related companies

- [Hightide Therapeutics](https://aibio.space/companies/hightide-therapeutics/) HKEX: 2511
- [Chongqing Lummy Pharmaceutical Co.](https://aibio.space/companies/chongqing-lummy-pharmaceutical/) SZSE: 300006
- [Jinghua Pharmaceutical Group Co.](https://aibio.space/companies/jinghua-pharmaceutical/) SZSE: 002349
- [Sichuan Kelun-Biotech Biopharmaceutical Co.](https://aibio.space/companies/sichuan-kelun-biotech-biopharmaceutical/) HKEX: 6990
- [Wanbangde Pharmaceutical Holding Group Co.](https://aibio.space/companies/wanbangde-pharmaceutical/) SZSE: 002082
- [Beijing Foyou Pharma Co.](https://aibio.space/companies/beijing-foyou-pharma/) SSE: 601089
- [Sinopep-Allsino Bio Pharmaceutical Co.](https://aibio.space/companies/sinopep-allsino-bio-pharmaceutical/) SSE: 688076
- [Zhejiang Xianju Pharmaceutical Co.](https://aibio.space/companies/zhejiang-xianju-pharmaceutical/) SZSE: 002332

### Also on HKEX

- [CANbridge Pharmaceuticals](https://aibio.space/companies/canbridge-pharmaceuticals/) 1228
- [Beijing Luzhu Biotechnology Co.](https://aibio.space/companies/beijing-luzhu-biotechnology/) 2480
- [Laekna](https://aibio.space/companies/laekna/) 2105
- [Jacobson Pharma Corporation](https://aibio.space/companies/jacobson-pharma/) 2633
- [Guangzhou Innogen Pharmaceutical Group Co](https://aibio.space/companies/guangzhou-innogen-pharmaceutical/) 2591
- [China Traditional Chinese Medicine Holdings Co.](https://aibio.space/companies/china-traditional-chinese-medicine/) 570

## Questions about ImmuneOnco Biopharmaceuticals (Shanghai)

What is the ticker symbol of ImmuneOnco Biopharmaceuticals (Shanghai)?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc trades under the ticker 1541 on HKEX.

Where is ImmuneOnco Biopharmaceuticals (Shanghai) listed?

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is listed on HKEX. Our directory also records these other listings: LSX:A3ETCF.

Which country or territory is ImmuneOnco Biopharmaceuticals (Shanghai) listed under?

Our directory records ImmuneOnco Biopharmaceuticals (Shanghai) Inc under China.

What does ImmuneOnco Biopharmaceuticals (Shanghai) do?

Our directory classifies ImmuneOnco Biopharmaceuticals (Shanghai) Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of ImmuneOnco Biopharmaceuticals (Shanghai)?

The ISIN recorded for ImmuneOnco Biopharmaceuticals (Shanghai) Inc is CNE100006624.

Does aibio.space cover ImmuneOnco Biopharmaceuticals (Shanghai)?

aibio.space lists ImmuneOnco Biopharmaceuticals (Shanghai) Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to ImmuneOnco Biopharmaceuticals (Shanghai)?

Companies in our directory listed in the same country and business area as ImmuneOnco Biopharmaceuticals (Shanghai): Hightide Therapeutics, Chongqing Lummy Pharmaceutical Co., Jinghua Pharmaceutical Group Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Wanbangde Pharmaceutical Holding Group Co., Beijing Foyou Pharma Co..

## Investor discussion: ImmuneOnco Biopharmaceuticals (Shanghai)

Members talk about ImmuneOnco Biopharmaceuticals (Shanghai) (1541). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at ImmuneOnco Biopharmaceuticals (Shanghai), newest first. Each line links the filing it comes from.

1. 2026-06-17 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061701972.pdf)
2. 2026-05-22 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052201702.pdf)
3. 2026-04-30 Financings Share or debt issue: (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT; (5) 2025 PROFIT DISTRIBUTION PLAN; (6) RE-APPOINTMENT OF AUDITOR; (7) 2026 DIRECTORS REMUNERATION PLAN; (8) 2026 SUPERVISORS REMUNERATION PLAN; (9) GENERL MANDATE TO ISSUE NEW SHARES; (10) GENERAL MANDATE TO REPURCHASE H SHARES; AND NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043001452.pdf)
4. 2025-11-20 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS - REDEMPTIONS AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1120/2025112001304.pdf)
5. 2025-10-16 Financings Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1016/2025101600159.pdf)
6. 2025-10-08 Financings Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1009/2025100900167.pdf)
7. 2025-06-16 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0616/2025061601563.pdf)
8. 2025-05-27 Mergers Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0527/2025052701539.pdf)
9. 2025-03-25 Mergers Transaction under the Listing Rules: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED CHANGE IN USE OF PROCEEDS. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0325/2025032502175.pdf)
10. 2025-02-21 Mergers Transaction under the Listing Rules: COMPLETION OF DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0221/2025022100767.pdf)
11. 2025-02-17 Mergers Transaction under the Listing Rules: (REVISED) SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0217/2025021700913.pdf)
12. 2025-01-10 Mergers Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0110/2025011000885.pdf)
13. 2024-12-30 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1230/2024123001467.pdf)
14. 2024-11-28 Financings Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1128/2024112801025.pdf)
15. 2024-11-20 Financings Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1121/2024112100029.pdf)

## Press releases

Headlines of ImmuneOnco Biopharmaceuticals (Shanghai)'s own announcements, newest first. Each opens the full release on the newswire that carried it.

1. 2026-09-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - COMPLETION OF CAPITAL INCREASE OF A SUBSIDIARY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0928/2026092802029.pdf)
2. 2026-08-28 HKEXnews [(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082803358.pdf)
3. 2026-08-27 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT OF ADVANCED HCC](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0827/2026082701801.pdf)
4. 2026-08-26 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0826/2026082601763.pdf)
5. 2026-08-25 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082501141.pdf)
6. 2026-08-21 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE FDA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101339.pdf)
7. 2026-08-06 HKEXnews [VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE CAPITAL INCREASE OF A SUBSIDIARY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0807/2026080700031.pdf)
8. 2026-07-31 HKEXnews [SUPPLEMENTAL ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0731/2026073101737.pdf)
9. 2026-07-10 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II/III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF IgG4-RELATED DISEASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0710/2026071000181.pdf)
10. 2026-07-03 HKEXnews [ANNOUNCEMENT PURSUANT TO RULES 14A.36, 14A.39 AND 14A.46 OF THE LISTING RULES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0703/2026070203903.pdf)
11. 2026-06-18 HKEXnews [VOLUNTARY ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0618/2026061802024.pdf)
12. 2026-06-17 HKEXnews [DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0617/2026061701972.pdf)
13. 2026-06-08 HKEXnews [VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0608/2026060802072.pdf)
14. 2026-05-28 HKEXnews [POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0528/2026052801819.pdf)
15. 2026-05-22 HKEXnews [DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052201702.pdf)
16. 2026-05-19 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II RANDOMIZED AND PLACEBO-CONTROLLED TRIAL OF IMM0306 FOR THE TREATMENT OF SLE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0519/2026051901273.pdf)
17. 2026-04-30 HKEXnews [NOTICE OF THE ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043001570.pdf)
18. 2026-04-30 HKEXnews [(1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2025 ANNUAL REPORT; (4) 2025 FINAL FINANCIAL REPORT AND 2026 FINANCIAL BUDGET REPORT; (5) 2025 PROFIT DISTRIBUTION PLAN; (6) RE-APPOINTMENT OF AUDITOR; (7) 2026 DIRECTORS REMUNERATION PLAN; (8) 2026 SUPERVISORS REMUNERATION PLAN; (9) GENERL MANDATE TO ISSUE NEW SHARES; (10) GENERAL MANDATE TO REPURCHASE H SHARES; AND NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043001452.pdf)
19. 2026-03-30 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033003622.pdf)
20. 2026-03-25 HKEXnews [ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0325/2026032501875.pdf)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:1541 on TradingView](https://www.tradingview.com/symbols/HKEX-1541/).

## Listing details

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a public biotech or pharmaceutical company listed on HKEX under the ticker 1541, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: ImmuneOnco Biopharmaceuticals (Shanghai) Inc

- **Ticker**: 1541

- **Listing**: HKEX

- **Country or territory**: China

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: CNE100006624

- **Other listed symbols**: LSX:A3ETCF

- **Last quote in directory**: 2026-10-22

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-1541/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/immuneonco-biopharmaceuticals-shanghai/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ImmuneOnco Biopharmaceuticals (Shanghai) (1541) stock", 2026-10-31, https://aibio.space/companies/immuneonco-biopharmaceuticals-shanghai/